Zheng Yi, Ph.D.

DepartmentUrology  

Medical SchoolPeking University Health Science Center, China

Academic RankAssociate Chief Physician


Appointment

Clinical / Research Interests

Endo-urological operations for prostate disease

Urinary stone and urinary tract tumor

Professional Highlights

Professional Appointments

Member, Urology Branch, China Sexology Association

Education Experience

Ph.D., Peking University Health Science Center, 2010-2013  

Master's degree, Zhejiang University School of Medicine, 2003-2006  

Bachelor's degree, Zhejiang University School of Medicine, 1998-2003  


Research Summary

Dr. Zheng specializes in the standardized and precise treatment of urological diseases, including prostate diseases (benign prostatic hyperplasia and prostate tumor), urinary tract stones and tumors.

Publications

Zheng Y, Bai F, Zhang N, Wu H. Analysis of Voiding Impairment after Prostate Biopsy and the Effect of Doxazosin Treatment: Outcomes from a Regional Cancer Center. Urol Int. 2022;106(1):97-102.

Zheng Y, Zhang Z, Zhang N. Protective Effects of Butyrate on Renal Ischemia-Reperfusion Injury in Rats. Urol Int. 2019;102(3):348-355.

Zheng Y, Zhang Y, Zheng Y, Zhang N. Carnosol protects against renal ischemia-reperfusion injury in rats. Exp Anim. 2018 Nov 1;67(4):545-553.

Wang YP, Li G, Ma LL, Zheng Y, Zhang SD, Zhang HX, Qiu M, Ma X. Penehyclidine hydrochloride ameliorates renal ischemia-reperfusion injury in rats. J Surg Res. 2014 Jan;186(1):390-7.

Zheng Y, Lu M, Ma L, Zhang S, Qiu M, Ma X. Osthole ameliorates renal ischemia-reperfusion injury by inhibiting inflammatory response. Urol Int. 2013;91(3):350-6.

Zheng Y, Lu M, Ma L, Zhang S, Qiu M, Wang Y. Osthole ameliorates renal ischemia-reperfusion injury in rats. J Surg Res. 2013 Jul;183(1):347-54.



Current Program

Find People

Search by Family Name

Find A Department

Search by Departments